Canada Medical Device Licence Consultant

Scope and evidence must be confirmed before any paid tests or filings.

A Canada medical device licence consultant should answer four questions before a company commissions testing or files anything: is the product regulated as a medical device, what Canadian risk class applies, which business needs which licence, and what evidence is still missing? The output should be a documented decision and gap plan, not a promised approval.

Define the product and defend its classification

Start with the exact intended medical purpose, patient population, user, setting, operating principle and claims across labels, instructions, websites and sales materials. A foreign classification, CE mark or US FDA clearance does not determine the Canadian class.

Apply the Canadian Medical Devices Regulations, including Schedule 1: first test whether the product is a medical device; then assess the relevant non-IVD or IVD rules. Where more than one class applies, the higher class prevails. Software, diagnostic algorithms and drug-device combinations need particular scope analysis; Health Canada makes the final classification decision in a dispute.

Assemble a short classification dossier containing:

Proposed Canadian intended-use statement alongside all marketing and labelling claims.
Device architecture, functions, accessories, variants and any software or medicinal component.
Rule-by-rule classification rationale, alternative interpretations and unresolved technical facts.

Do not assume a device is Class I merely because it is non-invasive, sold online or approved abroad. Hold the route decision if the intended use is still changing.

Choose the licence route, not just a form

Canada distinguishes a product medical device licence (MDL) from a medical device establishment licence (MDEL). These answer different questions; an MDEL does not approve an individual Class II–IV device.

Choose the licence route, not just a form
Situation	Likely regulatory direction	Decision still needed
Product does not meet the medical-device definition	Document why an MDL or MDEL route is inapplicable to that product; check any other relevant product regime.	Would a revised medical claim change the conclusion?
Class I medical device	No product MDL under the ordinary pathway; an MDEL may be required for relevant manufacturing, importing or distribution activity, subject to applicable exemptions.	Who actually imports, distributes or sells it, and through which licensed entities?
Class II, III or IV medical device	The manufacturer generally needs a device MDL before ordinary import or sale; importers/distributors separately assess their MDEL duties and exemptions.	Is the applicant the manufacturer named on the device label, and does the MDSAP QMS certificate cover the applicable manufacture or design-and-manufacture scope?
Software, IVD, combination, family or changed licensed device	Resolve product boundary, applicable classification/application rules and whether an existing licence must be amended before selecting an execution track.	Which functions, components, indications or identifiers change the regulatory assessment?

A specific Class I manufacturer exemption under section 44(2)(d) applies where that manufacturer imports or distributes its own devices solely through a person holding an MDEL. Confirm the actual operators, every sales channel and the licensee’s status; direct-to-consumer or other arrangements require their own exemption analysis, not an assumption.

This is a triage matrix, not an exemption determination. Special access, investigational testing and other exceptional authorizations require separate fact-specific review; do not treat them as ordinary commercial approval.

Build the gap analysis before buying new evidence

An effective consultant maps each available document to the Canadian question it can actually answer, then labels it usable, adaptable or missing. The result should be an owner-assigned issue log rather than a generic request for every test report.

Build the gap analysis before buying new evidence
Evidence stream	Check against Canadian requirements	Decision or gap to record
Intended use, classification and labels	Compare all claims and variants with the proposed class and identified Schedule 1 rules.	Freeze or revise claims; resolve any conflicting product identity.
Company and supply-chain map	Identify legal manufacturer, importer, distributor, private-label roles and intended transaction flow.	Assign MDL/MDEL responsibilities and verify any claimed exemption.
Safety, performance and clinical file	Trace risks, verification/validation and clinical justification to Canadian indications; identify missing device-specific support.	Reuse relevant studies where justified, adapt the analysis or commission targeted work.
QMS, certificates and previous licences	Review the MDSAP certificate scope where an MDL is contemplated and reconcile device identifiers with any Canadian listing.	Correct certificate or listing mismatches before filing; do not assume other-country approval transfers.

For an ordinary Class II–IV MDL application, section 32 of the Regulations calls for a QMS certificate covering manufacture (Class II) or design and manufacture (Classes III–IV). Health Canada’s implementation guidance requires an MDSAP certificate from a recognized auditing organization. An ISO 13485 certificate by itself is not enough to establish acceptance: check the issuing body and certificate scope before relying on it. Exceptional authorization pathways must be assessed separately.

Decide what overseas evidence can be reused

Foreign dossiers can save preparation effort, but foreign market authorization is not an automatic Canadian MDL. Treat each document as evidence to evaluate, not as a substitute for Health Canada's decision.

Reuse: a relevant test, risk analysis or clinical evaluation if device design, indications, methods and currency remain applicable; explain equivalence and limitations.
Adapt: US/EU classifications, labelling, technical-file indexes and QMS records to Canadian terminology, scope and submission requirements.
Generate: additional evidence only after the class, intended use and specific unresolved safety or effectiveness question have been identified.

Set four decision gates and a responsible owner

A useful advisory engagement finishes with a written route opinion, uncertainty register, evidence matrix and sequence of decisions. It does not require the consultant to claim to be Health Canada or guarantee an outcome.

Gate 1 — Product boundary: approve the intended-use statement, classify each relevant function or variant and document alternative readings.
Gate 2 — Responsibility: name the manufacturer and each supply-chain operator; determine the MDL/MDEL split and check licence listings where relevant.
Gate 3 — Evidence: confirm MDSAP status where required, prioritize genuine safety/clinical gaps and specify which foreign records may be relied on with justification.
Gate 4 — Execution hand-off: authorize only the necessary testing and filing work, assign post-market/change-control owners and recheck the route if indications, design or operators change.

Where consulting stops and registration begins

This page owns the pre-filing classification, route and evidence decisions. Application forms, dossier assembly, regulator correspondence and subsequent licensing operations belong to the execution services. For a filing workstream, see

medical device licence registration service

medical device licensing services

Questions before you commission a consultant

Can an MDEL replace the manufacturer's Class II device licence?: No. The establishment licence authorizes covered establishment activities; it does not substitute for the manufacturer's product MDL where an MDL is required.
Can I use my FDA clearance or CE marking as the Canadian licence?: No automatic substitution follows from those approvals. Supporting test and clinical records may be reusable after a Canada-specific relevance assessment.
Does a Class I manufacturer always need its own MDEL?: Not necessarily. The actual activities and specific exemptions matter, including arrangements through appropriately licensed importers or distributors; document the transaction flow first.
What if our software provides recommendations but also performs diagnostic analysis?: Evaluate each claimed function, its impact on clinical management and the Canadian software guidance; do not classify the whole product from the word “wellness” alone.
Should we pay for new clinical trials before asking for classification advice?: Normally settle the intended use, class and evidence gap first. A need for new clinical data depends on the device and the adequacy of the available evidence, not on a generic rule that every device requires a trial.

Official legal and technical sources

Source check: 15 October 2026. Consult the legislation and currently effective guidance. Health Canada has published a replacement MDEL guide with an effective date of 14 December 2026; it is not yet the operative version on the date of this review.